<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/236EE082-5616-432A-8480-B1D454D53EDE"><gtr:id>236EE082-5616-432A-8480-B1D454D53EDE</gtr:id><gtr:firstName>Ying</gtr:firstName><gtr:surname>Sun</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/95C0601F-3A0B-496E-B290-6F131EB6A764"><gtr:id>95C0601F-3A0B-496E-B290-6F131EB6A764</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Corrigan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400897"><gtr:id>5CE06691-E462-4189-AED1-DDEBD306E1C2</gtr:id><gtr:title>Expression and functional role of cysteinyl leukotriene and prostaglandin E2 receptors in aspirin sensitive asthma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400897</gtr:grantReference><gtr:abstractText>About 10% of the 6 million patients in the UK with asthma, in addition to having to manage their disease with inhalers, suffer the additional peril of sudden, severe and sometimes fatal exacerbation of their disease when they take an aspirin or similar painkiller. These patients not only overproduce lipid mediators called cysteinyl leukotrienes, which are powerful pro-inflammatory and bronchoconstricting agents made by inflammatory cells in the lining of the airways, but also are more sensitive to both endogenous and exogenous leukotrienes. The recent cloning of two cysteinyl leukotriene receptors, CysLT1 and CysLT2, will enable us to investigate the hypothesis that increased sensitivity to leukotrienes in these patients reflects increased expression of one or both of these receptors on inflammatory and smooth muscle cells of the airways. Drugs which block one of these receptors, CysLT1, are already clinically available and have been shown to exert partial benefit in reducing disease severity in aspirin sensitive asthmatics. If our studies implicate both receptors, then this study will provide a rationale for the employment of drugs which block both receptors, which exist but are not yet in clinical use, or alternatively focus more attention on drugs such as zileuton which inhibit leukotriene synthesis, but which are not universally available (for example, they are not available in the UK). The other key question addressed by the proposed study is why only a proportion of asthmatics are sensitive to aspirin and similar cyclooxygenase-1 (COX-1) inhibitors. COX-1 mediates the production of prostanoids, also from membrane lipids. Recently it has become clear that certain prostanoids, particularly PGE2, inhibit or ?brake? the effects of leukotrienes in asthmatics. We hypothesise that this braking system is defective in aspirin sensitive asthmatics. This deficiency is unlikely to lie in deficient production of PGE2, since COX-1 inhibitors reduce PGE2 production in all asthmatics. We hypothesise that is it more likely due to reduced expression of PGE2 receptors on target inflammatory and muscle cells in aspirin sensitive patients. Again, with the recent cloning and characterisation of the 4 PGE2 receptors EP1-4, we are in a position to test this hypothesis. Again this may point the way to new approaches to therapy of aspirin sensitive asthma, for example with stable, selective EP receptor agonists. In both cases, many thousands of patients will benefit, moreover in the relatively short term.</gtr:abstractText><gtr:technicalSummary>We will examine critical new aspects of the role of eicosanoids in the pathogenesis of aspirin-sensitive asthma. We hypothesise that aspirin-sensitive, as compared with non-aspirin-sensitive asthmatics matched for disease severity and therapy, show:
(1) Elevated expression of both cysteinyl leukotriene receptors CysLT1 and CysLT2 on inflammatory leukocytes and smooth muscle within the bronchial mucosa; (2) Reduced expression of one or more prostaglandin E2 (PGE2) receptors on inflammatory leukocytes and smooth muscle within the bronchial mucosa.
We further hypothesise that these differences in CysLT1, CysLT2 and PGE2 receptor expression result in the following functional consequences in aspirin-sensitive asthmatics: (1) Enhanced bronchoconstrictor response to inhaled cysteinyl leukotriene in vivo which correlates with bronchial mucosal CysLT receptor expression; (2) Impaired inhibition by PGE2 of asthma-related cytokine and cysteinyl leukotriene production by blood mononuclear cells and eosinophils respectively. Blood samples and bronchial biopsies will be obtained from 15 aspirin sensitive and 15 matched, tolerant asthmatics (dictated by powering) as well as 15 normal controls. Expression of the cysteinyl leukotriene receptors CysLT1 and CysLT2, and the PGE2 receptors EP1-4 on bronchial mucosal leukocytes and smooth muscle will be determined at the mRNA and protein levels by immunohistochemistry using specific antibodies, and in situ hybridisation using digoxigenin-labelled riboprobes. The phenotypes of leukocytes expressing receptors will be identified by sequential IHC/ISH. Receptor expression on bronchial smooth muscle will be measured using automated, quantitative image analysis. Our hypothesis is that both CysLT1 and CysLT2 are over-expressed, and one or more EP receptors are differentially expressed in aspirin-sensitive asthmatics as compared with non-aspirin-sensitive asthmatics and controls. As functional correlates, we will look for a reciprocal relationship between CysLT1/2 expression and PGE2 receptor expression, and between CysLT1/2 expression and bronchial responsiveness to inhaled LTE4 in vivo, and a relationship between EP receptor expression and the ability of PGE2 or EP receptor-specific analogues to inhibit IL-5 and cysteinyl leukotriene production by activated blood mononuclear cells and eosinophils respectively from these patients in vitro.</gtr:technicalSummary><gtr:fund><gtr:end>2009-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>199779</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BLF Webinar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BEF481F4-E091-4C3F-80A5-0EB058C79A3D</gtr:id><gtr:impact>65 asthma patiernts participated in Webinar organised by the Bristish Lung Foundation for a discsssion on the role of allergy and allergen avoidance in asthma

Much appreciative feedback to the British Lung Foundation</gtr:impact><gtr:outcomeId>ZpPeaqu1cAQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre web site</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>08C449F9-47D2-433E-83B8-4430501EDE08</gtr:id><gtr:impact>Web site and press relaeses

Asthma UK made aware of the possibility that omalizumab may in theory be suirable to treat non-atopic patients</gtr:impact><gtr:outcomeId>55DBDCC5C56</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4761430</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>United Kingdom Refractory Asthma Stratification Programme (RASP-UK)</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M016579/1</gtr:fundingRef><gtr:id>1249EF9A-7A18-49F7-93B2-5B000AB3B3A7</gtr:id><gtr:outcomeId>56d6eb68a2c246.91096952</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>420000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:fundingOrg>Boehringer Ingelheim</gtr:fundingOrg><gtr:id>605DC8AD-AA5F-468B-A2B2-A277BD725F48</gtr:id><gtr:outcomeId>BFpDDU6A7M60</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (G0501746 Molecular biology and cellular mechanisms of aspirin sensitive respiratory disease)</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4E69752C-5838-4A7B-9965-104AE5A8FCBF</gtr:id><gtr:outcomeId>486F42F52300</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>RASP-UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>76593345-6957-426F-A8D1-96A4202E52D1</gtr:id><gtr:outcomeId>56d6ecfd515d97.31703270</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Elisa for detevtion of human IgG aotoantibodies against IgE or the high-affinity IgE-receptor FceRI.</gtr:description><gtr:id>20358FF9-203A-47A6-B7E9-1FF1C0F5EA97</gtr:id><gtr:impact>Rapid screeeing tool for subset of non-atopic asthmartics expressing such antibodies.</gtr:impact><gtr:outcomeId>MxWTQ4NC2m9</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IgE autoantibody ELISA</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>sSyetm for direct, ex vivo culture of resected nasal polyps from patients with aspirin sensitive rhinosinusitis to study eicoasoind metablism and its regulation by drugs such as COX-1 inhibitors usinmg cell proportions directly exe vivo</gtr:description><gtr:id>7E492E02-B023-4D2A-B5FE-E8410700BB35</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>Na1fYDws6Nt</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Ex vivo prostanoid production</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In house allergen compoent resolved diagnosis (ISAC) facility</gtr:description><gtr:id>8861D8D2-C0A8-40BC-94F7-A9DD61DD3B8B</gtr:id><gtr:impact>Analysis of the IgE repertoire in biological samples such as bronchial biopsies</gtr:impact><gtr:outcomeId>a8KCD2xvFUQ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ISAC</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>45CE8111-0F61-44BD-91DD-18FF2A459DD5</gtr:id><gtr:title>The treatment targets of asthma: from laboratory to clinic.</gtr:title><gtr:parentPublicationTitle>Inflammation &amp; allergy drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35a04dc9752be2d58bc51f6d2ccc4ee8"><gtr:id>35a04dc9752be2d58bc51f6d2ccc4ee8</gtr:id><gtr:otherNames>Fang C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1871-5281</gtr:issn><gtr:outcomeId>3F3D772180C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>917B7725-2D03-4FB0-841A-8AD66DF7BBBC</gtr:id><gtr:title>Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/466033ad49019ef0f32ed5242943d919"><gtr:id>466033ad49019ef0f32ed5242943d919</gtr:id><gtr:otherNames>Ying S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>C7679BC49B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>254DCCE7-9346-486F-AC6B-B74C409A1C37</gtr:id><gtr:title>Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c71c2e38e2c4a66ed88e03590625cec6"><gtr:id>c71c2e38e2c4a66ed88e03590625cec6</gtr:id><gtr:otherNames>Corrigan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_12621_21_22418066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8738CA24-7784-403E-B897-2318F257B0B1</gtr:id><gtr:title>Role of cysteinyl leukotrienes in human allergen-specific Th2 responses induced by granulocyte macrophage-colony stimulating factor.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b76e9d83fe8a9ae8690c5ae5c4595cc8"><gtr:id>b76e9d83fe8a9ae8690c5ae5c4595cc8</gtr:id><gtr:otherNames>Faith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>aYvi3MBzVsg</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400897</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>